Published in N Engl J Med on August 11, 2009
Update on estrogens and the skeleton. J Clin Endocrinol Metab (2010) 1.25
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag (2010) 1.12
Measuring and improving adherence to osteoporosis pharmacotherapy. Curr Opin Rheumatol (2010) 0.93
Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility. Ther Clin Risk Manag (2012) 0.90
Strawberry notch homologue 2 regulates osteoclast fusion by enhancing the expression of DC-STAMP. J Exp Med (2013) 0.86
Nuclear receptors in bone physiology and diseases. Physiol Rev (2013) 0.86
The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis. Osteoporos Int (2011) 0.85
Pharmacogenomics of endocrine therapy in breast cancer. J Hum Genet (2013) 0.84
New treatment modalities in osteoporosis. Endocr Pract (2011) 0.80
Is nitroglycerin a novel and inexpensive treatment for osteoporosis? JAMA (2011) 0.79
Five-year follow-up study of a kidney-tonifying herbal Fufang for prevention of postmenopausal osteoporosis and fragility fractures. J Bone Miner Metab (2012) 0.78
Aryl hydrocarbon receptors in osteoclast lineage cells are a negative regulator of bone mass. PLoS One (2015) 0.76
Bone loss and fractures in limbs paralyzed by spinal cord injury: Prevention, diagnosis, and treatment. J Spinal Cord Med (2014) 0.76
Approaches to treating osteoporosis. Rev Obstet Gynecol (2009) 0.75
Can denosumab be a substitute, competitor, or complement to bisphosphonates? Korean J Pain (2017) 0.75
Bisphosphonates and atypical subtrochanteric fractures of the femur. Bone Joint Res (2017) 0.75
Increased Bone Mass in Female Mice Lacking Mast Cell Chymase. PLoS One (2016) 0.75
Intravenous zoledronate for osteoporosis: less might be more. Ther Adv Musculoskelet Dis (2016) 0.75
Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned. Endocr Rev (2017) 0.75
Evaluation of Osteogenesis and Angiogenesis of Icariin in Local Controlled Release and Systemic Delivery for Calvarial Defect in Ovariectomized Rats. Sci Rep (2017) 0.75
[Novel anti-osteoporotic drugs on the horizon]. Z Rheumatol (2016) 0.75
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 10.02
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med (2009) 6.67
Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med (2008) 4.81
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73
Building bone to reverse osteoporosis and repair fractures. J Clin Invest (2008) 2.40
Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med (2009) 2.27
DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med (2006) 7.90
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev (2002) 6.38
Osteoporosis: now and the future. Lancet (2011) 5.81
Circulating osteoblast-lineage cells in humans. N Engl J Med (2005) 4.19
Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res (2004) 4.02
Fat tissue, aging, and cellular senescence. Aging Cell (2010) 3.34
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest (2003) 3.09
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res (2008) 2.76
Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2008) 2.57
Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A (2008) 2.39
Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women. J Clin Endocrinol Metab (2010) 2.33
For estimating creatinine clearance measuring muscle mass gives better results than those based on demographics. Kidney Int (2009) 2.32
Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res (2005) 2.15
Contribution of in vivo structural measurements and load/strength ratios to the determination of forearm fracture risk in postmenopausal women. J Bone Miner Res (2007) 2.11
Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res (2008) 2.07
Bone turnover across the menopause transition: correlations with inhibins and follicle-stimulating hormone. J Clin Endocrinol Metab (2006) 2.04
The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev (2005) 2.03
Age-dependence of femoral strength in white women and men. J Bone Miner Res (2010) 2.03
Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res (2011) 2.00
Structural determinants of vertebral fracture risk. J Bone Miner Res (2007) 1.97
Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol (2012) 1.94
Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2009) 1.90
In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res (2014) 1.90
Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun (2005) 1.89
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab (2010) 1.87
Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERalpha or ERbeta. J Cell Biochem (2003) 1.76
Bone structure at the distal radius during adolescent growth. J Bone Miner Res (2009) 1.74
The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis. Endocrinology (2010) 1.74
Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res (2009) 1.59
Role of circulating osteogenic progenitor cells in calcific aortic stenosis. J Am Coll Cardiol (2012) 1.59
Mesenchymal stem cells for bone repair and metabolic bone diseases. Mayo Clin Proc (2009) 1.59
Age- and sex-specific differences in the factor of risk for vertebral fracture: a population-based study using QCT. J Bone Miner Res (2006) 1.58
Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. J Am Coll Cardiol (2008) 1.55
Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res (2011) 1.53
Effects of estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure in recently postmenopausal women. J Clin Endocrinol Metab (2013) 1.51
Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov (2011) 1.48
Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem (2003) 1.48
Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. Mol Endocrinol (2005) 1.48
Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res (2002) 1.46
Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. J Bone Miner Res (2003) 1.42
Fracture risk following bilateral orchiectomy. J Urol (2003) 1.41
Remodeling and vascular spaces in bone. J Bone Miner Res (2007) 1.39
Relationship of age to bone microstructure independent of areal bone mineral density. J Bone Miner Res (2012) 1.37
Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. J Bone Miner Res (2007) 1.35
Relation of vertebral deformities to bone density, structure, and strength. J Bone Miner Res (2010) 1.32
Nonoxidative free fatty acid disposal is greater in young women than men. J Clin Endocrinol Metab (2010) 1.31
Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab (2006) 1.30
Effects of loss of steroid receptor coactivator-1 on the skeletal response to estrogen in mice. Endocrinology (2003) 1.28
Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res (2003) 1.28
Contributions of bone density and structure to fracture risk assessment in men and women. Osteoporos Int (2005) 1.27
Characterization of circulating osteoblast lineage cells in humans. Bone (2007) 1.27
Robust QCT/FEA models of proximal femur stiffness and fracture load during a sideways fall on the hip. Ann Biomed Eng (2010) 1.26
A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metab (2008) 1.26
Higher muscle protein synthesis in women than men across the lifespan, and failure of androgen administration to amend age-related decrements. FASEB J (2008) 1.24
Population-based analysis of the relationship of whole bone strength indices and fall-related loads to age- and sex-specific patterns of hip and wrist fractures. J Bone Miner Res (2005) 1.24
Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways. J Bone Miner Res (2005) 1.23
Cortical porosity identifies women with osteopenia at increased risk for forearm fractures. J Bone Miner Res (2014) 1.21
High serum IGFBP-2 is predictive of increased bone turnover in aging men and women. J Bone Miner Res (2007) 1.21
Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. Diabetes Care (2007) 1.20
Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women. Bone (2011) 1.19
Female reproductive system and bone. Arch Biochem Biophys (2010) 1.19
Osteoporosis assessment by whole body region vs. site-specific DXA. Osteoporos Int (2005) 1.17
Dose-response of estrogen on bone versus the uterus in ovariectomized mice. Eur J Endocrinol (2004) 1.16
Emerging role of circulating calcifying cells in the bone-vascular axis. Circulation (2012) 1.11
Coronary endothelial dysfunction in humans is associated with coronary retention of osteogenic endothelial progenitor cells. Eur Heart J (2010) 1.11
Placebo-controlled trials in osteoporosis--proceeding with caution. N Engl J Med (2010) 1.11
Human embryonic stem cell-derived CD34+ cells function as MSC progenitor cells. Bone (2010) 1.10
Physiology of bone loss. Radiol Clin North Am (2010) 1.09
Relation of serum serotonin levels to bone density and structural parameters in women. J Bone Miner Res (2010) 1.09
Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res (2004) 1.08
Association of hip strength estimates by finite-element analysis with fractures in women and men. J Bone Miner Res (2011) 1.07
Skeletal stem/osteoprogenitor cells: current concepts, alternate hypotheses, and relationship to the bone remodeling compartment. J Cell Biochem (2008) 1.06
Androgens and bone. Steroids (2008) 1.05
Editorial: Sex hormone binding globulin: inhibitor or facilitator (or both) of sex steroid action? J Clin Endocrinol Metab (2006) 1.04
Two years of treatment with dehydroepiandrosterone does not improve insulin secretion, insulin action, or postprandial glucose turnover in elderly men or women. Diabetes (2007) 1.04
Effects of chronic estrogen treatment on modulating age-related bone loss in female mice. J Bone Miner Res (2010) 1.04
Characterization of mesenchymal progenitor cells isolated from human bone marrow by negative selection. Bone (2011) 1.04
Fracture risk in women with breast cancer: a population-based study. J Bone Miner Res (2012) 1.03
Multicenter precision of cortical and trabecular bone quality measures assessed by high-resolution peripheral quantitative computed tomography. J Bone Miner Res (2013) 1.02
A potentially deleterious role of IGFBP-2 on bone density in aging men and women. J Bone Miner Res (2004) 1.02
Estrogen and bone: insights from estrogen-resistant, aromatase-deficient, and normal men. Bone (2008) 1.01
Trends in fracture incidence: a population-based study over 20 years. J Bone Miner Res (2014) 1.01
Fracture risk in men with prostate cancer: a population-based study. J Bone Miner Res (2011) 1.00
Skeletal muscle mass is associated with bone geometry and microstructure and serum insulin-like growth factor binding protein-2 levels in adult women and men. J Bone Miner Res (2012) 1.00
What accounts for rib fractures in older adults? J Osteoporos (2011) 1.00
Estrogen receptor beta isoform-specific induction of transforming growth factor beta-inducible early gene-1 in human osteoblast cells: an essential role for the activation function 1 domain. Mol Endocrinol (2008) 1.00
Relationship of sympathetic activity to bone microstructure, turnover, and plasma osteopontin levels in women. J Clin Endocrinol Metab (2012) 0.99
Abdominal aortic calcification, BMD, and bone microstructure: a population-based study. J Bone Miner Res (2008) 0.99
Potential role of pancreatic and enteric hormones in regulating bone turnover. J Bone Miner Res (2005) 0.99
Subcutaneous administration of insulin-like growth factor (IGF)-II/IGF binding protein-2 complex stimulates bone formation and prevents loss of bone mineral density in a rat model of disuse osteoporosis. Growth Horm IGF Res (2002) 0.99
Bone strength and structural deficits in children and adolescents with a distal forearm fracture resulting from mild trauma. J Bone Miner Res (2014) 0.99
Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. Eur J Endocrinol (2002) 0.98
Applications of a New Handheld Reference Point Indentation Instrument Measuring Bone Material Strength. J Med Device (2013) 0.98
Parathyroid hormone plus alendronate--a combination that does not add up. N Engl J Med (2003) 0.98
Effects of intermittent parathyroid hormone treatment on osteoprogenitor cells in postmenopausal women. Bone (2011) 0.98
Effects of physiological variations in circulating insulin levels on bone turnover in humans. J Clin Endocrinol Metab (2011) 0.97
Proximal femoral density distribution and structure in relation to age and hip fracture risk in women. J Bone Miner Res (2013) 0.97